

Product Data Sheet

Product Name: ABS-752 hydrochloride

Cat. No.: GC81777

Chemical Properties

Cas. No. 2922884-90-8

Formula $C_{14}H_{15}ClFN_3O_3$ M.Wt 327.74

Solubility DMSO: 25 mg/mL (76.28 mM; Need ultrasonic) Storage Store at 4°C, sealed storage, away from moisture

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

ABS-752 hydrochloride is an orally active prodrug targeting CRBN-modulating molecular glue with selectivity in protein degradation. ABS-752 hydrochloride preferentially degrades GSPT1 and induces cytotoxicity through this degradation, while it also degrades NEK7, SALL4 and CK1 α , with weaker degradation potency against CK1 α . As a prodrug, ABS-752 hydrochloride requires metabolic activation to ABT-002 to form the active complex; VAP-1 mediates its conversion to an aldehyde intermediate. ABS-752 hydrochloride induces cell death, reduces cell viability, and exhibits antitumor activity, leading to regression and inhibition of tumor growth. ABS-752 hydrochloride shows no

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

cytotoxicity in primary human hepatocytes. ABS-752 hydrochloride can be used in the research of hepatocellular carcinoma [1].

In Vivo, ABS-752 (1-10 mg/kg; p.o.; BID; 14 days) hydrochloride exhibits exceptional antitumor efficacy in the Hep3B xenograft model, with complete tumor regression observed at the 10 mg/kg BID dose[1]. ABS-752 (100 mg/kg; p.o.; BID; 20-21 days) hydrochloride induces tumor growth inhibition in 80% of tested HCC PDX models, with >50% TGI in four models and complete regression in one model at the 100 mg/kg BID dose[1]. ABS-752 (0.1 mg/kg; single dose) hydrochloride induces significant degradation of GSPT1 and NEK7 in non-human primates at a 0.1 mg/kg dose, with ~80% GSPT1 degradation observed 6 hours post-dose[1].

In Vitro, ABS-752 (72 h) hydrochloride exerts cytotoxic/cytostatic activity in 13 of 19 tested HCC cell lines, reducing viability by at least 50%[1]. ABS-752 (1-50 μ M; 72 h) hydrochloride reduces viability in wild-type Hep3B cells, but has no effect on Hep3B GSPT1G575N cells, demonstrating that GSPT1 degradation drives its cytotoxic activity[1]. ABS-752 (0.1 nM-30 μ M; 72 h) hydrochloride has viability-reducing activity in Hep3B cells that is dependent on VAP-1[1]. ABS-752 (6 h, 24 h) hydrochloride potently degrades GSPT1 (DC_{50} = 1 nM at 24 h), NEK7 (DC_{50} = 9 nM at 24 h), CK1 α (DC_{50} = 35 nM at 24 h) in Hep3B cells, and SALL4 (DC_{50} = 40 nM at 24 h) in Kelly cells, with GSPT1 as the primary target showing near-complete degradation at early time points[1]. ABS-752 (0.1 μ M; 6 h) hydrochloride preferentially degrades GSPT1, with greater degradation of NEK7 than CK1 α [1]. ABS-752 (1-10 μ M) hydrochloride does not form a biochemical ternary complex with CRBN and GSPT1, NEK7, CK1 α , or IKZF1, but shows recruitment activity with SALL4[1]. ABS-752 (10 μ M; 0-20 h) hydrochloride is converted to the aldehyde metabolite ABT-971 by recombinant mVAP-1[1]. ABS-752 (125-2500 μ M; 15 min) hydrochloride is oxidized by recombinant human VAP-1 with a K_m of 674 μ M[1].

References:

[1]. Glaza P, et al. Targeted degradation of GSPT1 and NEK7 by a molecular glue prodrug for treatment of HCC. Communications chemistry. 2025 Aug 14;8(1):247.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA